|
Q4 2017 Events
|
3
|
Resverlogix Corp.
|
Oct 21, 2017 08:14AM
|
|
Q4 2019 Events
|
12
|
Resverlogix Corp.
|
Oct 01, 2019 03:56PM
|
|
Q4 Events List Updated
|
7
|
Resverlogix Corp.
|
Oct 19, 2015 10:37AM
|
|
Q4 Events page updated
|
7
|
Resverlogix Corp.
|
Oct 11, 2016 03:29PM
|
|
Q4 for RVX and Zenith
|
9
|
Resverlogix Corp.
|
Oct 25, 2016 12:53PM
|
|
Q4 for RVX and Zenith
|
5
|
Zenith Epigenetics
|
Oct 25, 2016 12:54PM
|
|
Quarterly filings 10/30/17
|
1
|
BIOASIS TECHNOLOGIES INC
|
Oct 31, 2017 03:39PM
|
|
Questioning Expectations vs. Results
|
|
BIOASIS TECHNOLOGIES INC
|
Jun 01, 2017 02:15PM
|
|
Questions for Q1 webcast
|
7
|
Resverlogix Corp.
|
Mar 03, 2016 01:44PM
|
|
Quiet Before the Bang
|
|
BIOASIS TECHNOLOGIES INC
|
Jun 01, 2017 02:06PM
|
|
RAAS Inhibitors in Patients with Covid-19
|
6
|
Resverlogix Corp.
|
Mar 31, 2020 07:29AM
|
|
Rationale & Design paper and End of Dosing Announcement
|
5
|
Resverlogix Corp.
|
Apr 16, 2019 11:10AM
|
|
Rationale and Design of Apabetalone BETonMACE Trial
|
3
|
Resverlogix Corp.
|
Dec 03, 2018 03:32PM
|
|
Re-visiting Tundup's all-time top-rated message
|
4
|
Resverlogix Corp.
|
Jan 22, 2019 11:31AM
|
|
Re: "57% relative risk reduction of MACE in patients with diabetes mellitus (DM) and CVD..."
|
2
|
Resverlogix Corp.
|
Aug 13, 2018 10:20PM
|
|
Re: "57% relative risk reduction of MACE in patients with diabetes mellitus (DM) and CVD..."
|
5
|
Resverlogix Corp.
|
Aug 14, 2018 09:21AM
|
|
Re: "Anti-aging" drug research: Off-topic to RVX or maybe quite related?
|
5
|
Resverlogix Corp.
|
Aug 29, 2018 05:45PM
|
|
Re: "Getting cancer drugs into the brain" article in Nature Outlooks mentions BiOasis
|
5
|
BIOASIS TECHNOLOGIES INC
|
Oct 01, 2018 10:20PM
|
|
Re: "ONE of the KEY patents !"
|
1
|
Resverlogix Corp.
|
Mar 15, 2017 09:42AM
|
|
Re: "Targeted" Trial design
|
12
|
Resverlogix Corp.
|
Feb 04, 2021 04:46PM
|
